Get the Stockscreener App
7.39
1.79%
0.13
Pre-market:
7.01
-0.38
-5.14%
Kura Oncology Inc stock is traded at $7.39, with a volume of 2.90M.
It is up +1.79% in the last 24 hours and down -17.98% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
See More
Previous Close:
$7.26
Open:
$7.35
24h Volume:
2.90M
Relative Volume:
1.74
Market Cap:
$562.97M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-3.4055
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
+1.79%
1M Performance:
-17.98%
6M Performance:
-64.73%
1Y Performance:
-49.69%
1-Day Range:
$7.20
$7.435
1-Week Range:
$7.02
$7.66
52-Week Range:
$6.98
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
7.39 | 562.97M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Assenagon Asset Management S.A. Sells 146,879 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Up 17.4% in December - MarketBeat
JPMorgan Chase & Co. Boosts Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Harbor Capital Advisors Inc. Boosts Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology secures new headquarters in San Diego - Investing.com India
Kura Oncology secures new headquarters in San Diego By Investing.com - Investing.com Australia
Kura Oncology stock hits 52-week low at $8.38 amid market challenges - Investing.com Nigeria
Kura Oncology (NASDAQ:KURA) Sets New 12-Month LowTime to Sell? - MarketBeat
Brokers Set Expectations for Kura Oncology FY2029 Earnings - Defense World
Brokers Offer Predictions for Kura Oncology FY2029 Earnings - MarketBeat
BlackRock, Inc. Increases Stake in Kura Oncology Inc - GuruFocus.com
Long Term Trading Analysis for (KURA) - Stock Traders Daily
Scotiabank Cuts Kura Oncology (NASDAQ:KURA) Price Target to $10.00 - MarketBeat
Kura Oncology announces executive changes and settlement By Investing.com - Investing.com Australia
Kura Oncology announces executive changes and settlement - Investing.com India
Kura Oncology appoints new CMO and CSO By Investing.com - Investing.com Australia
Kura Oncology (NASDAQ:KURA) Sets New 1-Year LowTime to Sell? - MarketBeat
Kura Oncology Announces Leadership Changes and Appointments - MSN
Kura Oncology Promotes New Chief Medical Officer - MarketWatch
Kura Oncology appoints new CMO and CSO - Investing.com
Kura Oncology Announces Senior Executive Promotions - The Manila Times
Kura Oncology (NASDAQ:KURA) Hits New 12-Month LowHere's Why - MarketBeat
Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover - MSN
Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Buy” by Analysts - Defense World
Objective long/short (KURA) Report - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Sets New 12-Month Low – Here’s What Happened - Defense World
Kura Oncology's Stock Sinks To US$8.94, But Insiders Sold Even Lower - Simply Wall St
Kura Oncology (NASDAQ:KURA) Reaches New 12-Month LowWhat's Next? - MarketBeat
Kura Oncology stock hits 52-week low at $8.83 amid market challenges - Investing.com Australia
Kura Oncology expands stock option plan - Investing.com India
Kura Oncology expands stock option plan By Investing.com - Investing.com UK
Kura Oncology (NASDAQ:KURA) Reaches New 52-Week LowWhat's Next? - MarketBeat
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade) (NASDAQ:KURA) - Seeking Alpha
(KURA) Proactive Strategies - Stock Traders Daily
Kura, Kyowa highlight positive combo data for ziftomenib - BioWorld Online
Kura Oncology's SWOT analysis: ziftomenib's promise buoys stock outlook By Investing.com - Investing.com UK
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook By Investing.com - Investing.com South Africa
Kura Oncology's SWOT analysis: ziftomenib's promise drives stock outlook - Investing.com India
Kura Oncology's SWOT analysis: ziftomenib's potential reshapes cancer stock landscape - Investing.com Canada
Kura Oncology’s (KURA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Call Transcript - MSN
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting - The Manila Times
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):